Loading...

Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible - Hallo friend HEALTHY LIVING, In the article you read this time with the title Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible, we have prepared well for this article you read and download the information therein. hopefully fill posts items ENTERTAINMENT, items FITNES, items HEALTHY, items HEALTHY FOOD, items HEALTHY LIVING, items HOW HEALTHY, we write this you can understand. Well, happy reading.

Title : Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible
link : Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible

Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible

From The Lancet:

Small molecule inhibitors of Janus kinase (JAK)

Much of the recent knowledge of the underlying mechanisms that drive rheumatoid arthritis and other diseases has come from preclinical studies of key cytokines, including tumour necrosis factor alpha, interleukin 6, and granulocyte–macrophage colony-stimulating factor. New Janus kinase (JAK) inhibitors include tofacitinib and baricitinib which are approved for treatment of arthritis and other rheumatoid diseases.

Aggressive treatment, early

For a complex, progressive, chronic disease such as rheumatoid arthritis, the timing of intervention is critical. In the past, the recommended treatment approach was slow and steady, referred to as “the pyramid”—ie, a base of physical therapy and non-pharmacological interventions, followed by conservative treatment with non-steroidal anti-inflammatory drugs, then glucocorticoid steroids and, finally, administration of a conventional disease-modifying antirheumatic drug (DMARD). This concept is now inverted. Intensive intervention, initiated earlier, with conventional and biological DMARDs is increasingly recommended.

Biologics and small molecule inhibitors are added to the therapeutic arsenal. Focus on early window of opportunity for management, with treat-to-target approaches that include rapid intervention, and adjustment of medications for patients who do not achieve remission within 6 months. The new campaign, “Don't delay, connect today”, highlights this approach.

Affordability

Biosimilars might provide affordable options.

An unprecedented range of therapeutic options for rheumatic diseases is now available—the new challenge is to make them accessible.

References:

A platinum age for rheumatology - The Lancet http://buff.ly/2slCFPw

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.

via CasesBlog - Medical and Health Blog More READ

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Loading...

thus Article Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible

that is all articles Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible This time, hopefully can provide benefits to all of you. Okay, see you in another article posting.

You now read the article Unprecedented range of therapeutic options for rheumatic diseases is now available — challenge is to make them accessible with the link address https://healthylivingsimple.blogspot.com/2017/06/unprecedented-range-of-therapeutic.html

Tweet

Subscribe to receive free email updates: